Syndax Pharmaceuticals SNDX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$42.67M+49.7% | -$68.01M+27.8% | -$60.72M+27.8% | -$71.85M-5.6% | -$84.85M-17.2% | ||
| $12.05M+16.1% | $11.25M-8.5% | $12.08M+1.2% | $13.79M+39.3% | $10.38M+16.6% | ||
| -$50.35M+47.1% | -$69.49M-21.1% | -$70.54M-13.2% | -$87.8M-22.5% | -$95.16M-13.9% | ||
| $38.39M-59.2% | $81.58M+130% | $72.43M-16.6% | $41.89M— | $94.14M+195% | ||
| $7.92M+751% | $5.92M-98.3% | $6.28M+103% | $551K-18.5% | $930K-57.1% | ||
| -$4.04M-4,386% | —— | —— | -$45.36M-392% | -$90K+100.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Syndax Pharmaceuticals generate?
- Syndax Pharmaceuticals (SNDX) generated -$278.2M in operating cash flow over the trailing twelve months.
- Where does Syndax Pharmaceuticals's cash flow data come from?
- Every line is extracted from Syndax Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
